Hamer R R, Tegeler J J, Kurtz E S, Allen R C, Bailey S C, Elliott M E, Hellyer L, Helsley G C, Przekop P, Freed B S, White J, Martin L L
Hoechst-Roussel Pharmaceuticals Inc., Somerville, New Jersey 08876, USA.
J Med Chem. 1996 Jan 5;39(1):246-52. doi: 10.1021/jm950563z.
Hydroxylamine and hydroxamic acid derivatives of a known nonsteroidal antiinflammatory dibenzoxepine series display both cyclooxygenase (CO) and 5-lipoxygenase (5-LO) inhibitory properties. Many of these new dual CO/5-LO inhibitors also exhibit potent topical antiinflammatory activity in the arachidonic acid-induced murine ear edema model. On the basis of their promising profile of in vitro and in vivo activities, hydroxamic acids 24h, 3-(6,11-dihydro-11-oxodibenz[b,e]oxepin-2-yl)-N-hydroxy-N-++ +methylpropanamide (HP 977), and 25, 3-(6,11-dihydrodibenz[b,e]oxepin-2-yl)-N-hydroxy-N- methylpropanamide (P10294), were selected as developmental candidates for the topical treatment of inflammatory skin disorders.
已知的非甾体抗炎二苯并氧杂䓬系列的羟胺和异羟肟酸衍生物具有环氧化酶(CO)和5-脂氧合酶(5-LO)抑制特性。这些新型双重CO/5-LO抑制剂中的许多在花生四烯酸诱导的小鼠耳水肿模型中也表现出强大的局部抗炎活性。基于其有前景的体外和体内活性概况,异羟肟酸24h(3-(6,11-二氢-11-氧代二苯并[b,e]氧杂䓬-2-基)-N-羟基-N-甲基丙酰胺(HP 977))和25(3-(6,11-二氢二苯并[b,e]氧杂䓬-2-基)-N-羟基-N-甲基丙酰胺(P10294))被选为用于局部治疗炎症性皮肤病的开发候选药物。